Back to top
more

Flexion Therapeutics, Inc. (FLXN)

(Delayed Data from NSDQ)

$10.77 USD

10.77
466,068

+0.10 (0.94%)

Updated May 3, 2019 04:00 PM ET

After-Market: $10.75 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark

by Zacks Equity Research

Pacira's (PCRX) earnings beat estimates in the third quarter of 2021 while revenues miss the same. Its flagship product Exparel's sales rise year over year.

Earnings Preview: Flexion Therapeutics (FLXN) Q3 Earnings Expected to Decline

by Zacks Equity Research

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Flexion (FLXN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Flexion's (FLXN) third-quarter earnings call, investor focus will be on its updates on earnings and revenues and the upcoming merger with Pacira whereby the latter will acquire the former.

Flexion Therapeutics (FLXN) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Flexion Therapeutics (FLXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Why Flexion Therapeutics (FLXN) Could Be an Impressive Growth Stock

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Flexion Therapeutics (FLXN).

Down 24.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Flexion Therapeutics (FLXN)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Flexion Therapeutics (FLXN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Flexion Therapeutics (FLXN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 12.00% and 0.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Flexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for June 4th

by Zacks Equity Research

ASLN, BLRX, FLXN, ICMB, and MRNS have been added to the Zacks Rank #5 (Strong Sell) List on June 4, 2021.

Flexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Flexion Therapeutics (FLXN) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 9.09% and -1.09%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Flexion Therapeutics (FLXN) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Flexion Therapeutics (FLXN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -2.04% and 0.31%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Flexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Flexion Therapeutics (FLXN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -8.57% and -0.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Flexion Therapeutics (FLXN) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Flexion Therapeutics (FLXN) Is Up 9.84% in One Week: What You Should Know

by Zacks Equity Research

Does Flexion Therapeutics (FLXN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are Options Traders Betting on a Big Move in Flexion (FLXN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Flexion (FLXN) stock based on the movements in the options market lately.

Flexion Therapeutics (FLXN) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Flexion Therapeutics (FLXN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Flexion (FLXN) Soars: Stock Adds 6.6% in Session

by Zacks Equity Research

Flexion (FLXN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

How Flexion Therapeutics (FLXN) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Flexion Therapeutics (FLXN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Flexion Therapeutics (FLXN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 12.87% and 0.65%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Flexion Therapeutics (FLXN) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is the Options Market Predicting a Spike in Flexion (FLXN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Flexion (FLXN) stock based on the movements in the options market lately.

Flexion's (FLXN) Stock Up on FDA Approval for Zilretta sNDA

by Zacks Equity Research

Flexion's (FLXN) sNDA for osteoarthritis drug, Zilretta, seeking removal of confusing limitation of use label, gets FDA approval.